Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Starpharma, AstraZeneca deal

    Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer, Drug delivery AstraZeneca received rights to use Starpharma's DEP dendrimer drug …

    Published on 4/14/2014
  • Strox Biopharmaceuticals, Xbiotech deal

    Strox Biopharmaceuticals LLC, Wellington, Fla. XBiotech Inc., Austin, Texas Business: Infectious XBiotech acquired Strox's patent estate for an undisclosed antibody therapy for methicillin-resistant Staphylococcus …

    Published on 4/14/2014
  • Tetra Discovery, Broad Institute of MIT and Harvard deal

    Tetra Discovery Partners LLC, Grand Rapids, Mich. Broad Institute of MIT and Harvard, Cambridge, Mass. Business: Neurology Tetra partnered with the institute's Stanley Center for Psychiatric Diseases to evaluate the …

    Published on 4/14/2014
  • A1M Pharma, NeuroVive deal

    A1M Pharma AB (AktieTorget:A1M), Lund, Sweden NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Business: Endocrine/Metabolic A1M and NeuroVive partnered to conduct research in mitochondrial medicine. The companies …

    Published on 3/31/2014
  • Albany Molecular Research, Cedarburg Hauser deal

    Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y. Cedarburg Hauser Pharmaceuticals Inc., Grafton, Wis. Business: Supply/Service Albany Molecular will acquire contract developer and manufacturer Cedarburg for $…

    Published on 3/31/2014
  • Alnylam, Sanofi deal

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic, Hematology Sanofi's Genzyme Corp. unit paid Alnylam $23 million to purchase 344,…

    Published on 3/31/2014
  • Asahi Kasei Pharma, Vernalis deal

    Asahi Kasei Pharma Corp., Tokyo, Japan Vernalis plc (LSE:VER), Winnersh, U.K. Business: Autoimmune Vernalis will receive a 300,000 ($494,820) milestone payment under a 2013 deal with Asahi to use Vernalis' fragment and …

    Published on 3/31/2014
  • AstraZeneca, Sumitomo Chemical Co. Ltd. deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Sumitomo Chemical Co. Ltd. (Tokyo:4005), Tokyo, Japan Business: Pharmaceuticals AstraZeneca purchased the 20% stake of its AstraZeneca K.K. Japanese subsidiary owned by …

    Published on 3/31/2014
  • Bionamics GmbH, Evotec deal

    Bionamics GmbH, Hamburg, Germany Evotec AG (Xetra:EVT), Hamburg, Germany Business: Neurology, Autoimmune Evotec acquired asset management company Bionamics for an undisclosed amount in cash. Bionamics will be eligible …

    Published on 3/31/2014
  • Biotie, UCB deal

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology UCB terminated an amended 2010 deal with Biotie granting UCB exclusive, worldwide rights to Biotie's …

    Published on 3/31/2014
  • CytoVale, NetScientific, Thiel Foundation deal

    Cytovale Inc., South San Francisco, Calif. NetScientific plc (LSE:NSCI), Cambridge, U.K. Thiel Foundation, San Francisco, Calif. Business: Other Biotech IP commercialization firm NetScientific will purchase a …

    Published on 3/31/2014
  • Genable, Spark Therapeutics deal

    Genable Technologies Ltd., Dublin, Ireland Spark Therapeutics LLC, Philadelphia, Pa. Business: Gene/Cell therapy, Ophthalmic Spark granted Genable exclusive, worldwide rights to patents covering manufacturing of adeno-…

    Published on 3/31/2014
  • Genentech, Xenon, Roche deal

    Genentech Inc., South San Francisco, Calif. Xenon Pharmaceuticals Inc., Burnaby, B.C. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Neurology Xenon partnered with Roche's Genentech unit to discover and …

    Published on 3/31/2014
  • Genmab, J&J deal

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Genmab will receive a $22 million milestone payment from Johnson & Johnson's Janssen Biotech Inc.…

    Published on 3/31/2014
  • Genmab, MAB Discovery deal

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark MAB Discovery GmbH, Neuried, Germany Business: Antibodies Genmab partnered with MAB Discovery to discover antibodies against multiple undisclosed targets selected …

    Published on 3/31/2014
  • Guerbet, Sirtex Medical deal

    Guerbet S.A. (Euronext:GBT), Villepinte, France Sirtex Medical Ltd. (ASX:SRX), Sydney, Australia Business: Cancer, Diagnostic The companies partnered to develop Sirtex's SIR-Spheres microspheres and Guerbet's Lipiodol …

    Published on 3/31/2014
  • IntelliCell, New York University deal

    IntelliCell BioSciences Inc. (OTCQB:SVFC), New York, N.Y. New York University, New York, N.Y. Business: Neurology IntelliCell partnered with Manuel Trujillo, chief psychiatrist at Amen Clinics in New York and clinical …

    Published on 3/31/2014
  • Manchester Pharmaceuticals LLC, Retrophin deal

    Manchester Pharmaceuticals LLC, Fort Collins, Colo. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Cardiovascular, Gastrointestinal, Endocrine/Metabolic Retrophin completed its acquisition of fellow rare disease…

    Published on 3/31/2014
  • Myriad Genetics, Tesaro deal

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Pharmacogenetics Tesaro will use Myriad's Homologous Recombination Deficiency (HRD) test to identify tumor …

    Published on 3/31/2014
  • NanoBio, Merck deal

    NanoBio Corp., Ann Arbor, Mich. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious, Drug delivery NanoBio granted Merck exclusive, worldwide rights to NanoBio's nanoemulsion-based adjuvant …

    Published on 3/31/2014
  • New York Genome Center (NYGC), IBM Corp. deal

    New York Genome Center (NYGC), New York, N.Y. IBM Corp. (NYSE:IBM), Armonk, N.Y. Business: Pharmacogenetics IBM and the non-profit NYGC will jointly evaluate a prototype of IBM's Watson cognitive system designed as a …

    Published on 3/31/2014
  • Pacgen, General Biologicals Corp. deal

    Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. General Biologicals Corp. (GreTai-E:4117), Hsinchu, Taiwan Business: Genitourinary, Dermatology, Ophthalmic The companies closed a deal under which Pacgen granted …

    Published on 3/31/2014
  • Rosetta Genomics, Rabin Medical Center deal

    Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel Rabin Medical Center, Petah-Tikva, Israel Business: Diagnostic Rosetta and not-for-profit Rabin Medical Center partnered to develop a non-invasive microRNA-based …

    Published on 3/31/2014
  • Singulex, Tecan deal

    Singulex Inc., Alameda, Calif. Tecan AG (SIX:TECN), Mannedorf, Switzerland Business: Diagnostic The companies will co-develop the Sgx Clarity ultrasensitive immunoassay system for in vitro diagnostics. The system will …

    Published on 3/31/2014
  • SQI Diagnostics deal

    SQI Diagnostics Inc. (TSX-V:SQD), Toronto, Ontario Business: Pharmaceuticals SQI expanded its deal to develop a custom multiplex test for a drug from an undisclosed pharma. Under the expansion, SQI will develop a 21-…

    Published on 3/31/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993